Details for Patent: 10,561,659

Which drugs does patent 10,561,659 protect, and when does it expire?

Patent 10,561,659 protects LEQSELVI and is included in one NDA.

This patent has twenty patent family members in ten countries.

Summary for Patent: 10,561,659

Title:	Treatment of hair loss disorders with deuterated JAK inhibitors
Abstract:	Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
Inventor(s):	Wagner Amanda T., Cassella James V., Graham Philip B., Braman Virginia, Uttamsingh Vinita, Von Hehn Jana, Hamilton Colleen E.
Assignee:	Concert Pharmaceuticals, Inc.
Application Number:	US16098338
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,561,659

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA

International Family Members for US Patent 10,561,659

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017261286
Australia	2023201112
Brazil	112018072339
Canada	3022519